Hoth Therapeutics Competitors and Similar CompaniesClear all
Hoth Therapeutics's competitors and similar companies include Veloxis Pharmaceuticals and CorMedix.
 Hoth Therapeutics Hoth Therapeutics operates as a biopharmaceutical company that develops therapeutics for patients suffering from atopic dermatitis. |  Veloxis Pharmaceuticals Veloxis Pharmaceuticals is a biopharmaceutical company that identifies, develops, and commercializes products used in transplantation and adjacent therapies. |  CorMedix CorMedix is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney disease. | |
Founding Date | Founding Date N/A | Founding Date 2002 | Founding Date 2006 |
Type | Type Public | Type Subsidiary | Type Public |
Tags | |||
Locations | Locations New York, US HQ | Locations København, DK HQ Cary, US Cary, US | Locations Berkeley Heights, US HQ |
Employees | Employees 2 | Employees 54 | Employees 3036% increase |
Valuation ($) | Valuation ($) 6.7 m | Valuation ($) N/A | Valuation ($) 749.2 m |
Financial | |||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) kr39.5m (FY, 2018) | Revenue (est.) $311.7m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods kr7.9m (FY, 2018) | Cost of goods $22.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit kr31.6m (FY, 2018) | Gross profit $275.7m (FY, 2025) |
Net income | Net income ($12.5m) (FY, 2025) | Net income (kr5.3m) (FY, 2018) | Net income $163.1m (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 3.7m | Total funding raised $ 60m | Total funding raised $ 11.5m |
For sources of this data, please see the company profile
View Company Profiles
Veloxis Pharmaceuticals
HQ
København, DK
Veloxis Pharmaceuticals is a biopharmaceutical company that identifies, develops, and commercializes products used in transplantation and adjacent therapies.
View companyCorMedix
HQ
Berkeley Heights, US
Employees
30↑ 36% increase
CorMedix is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney disease.
View company